that support either the 2001 recommendations that have changed or the new or revised recommendations are cited in parentheses at the end of each recommendation or comment. A list of abbreviations is included in the Appendix. The reader is referred to the full-text guideline posted on the World Wide Web sites of the ACC, the AHA, and the SCAI for a more detailed explanation of the changes discussed here. Please note that we have changed the table of contents headings in the 2001 ACC/AHA Guidelines for Percutaneous Coronary Intervention from roman numerals to unique identifying numbers.
In preparing this update, the committee was guided by the following principles:
1. Changes in recommendations and levels of evidence were made because of the availability of data from new randomized trials, the accumulation of new clinical evidence, and/or the development of clinical consensus. 2. The committee is cognizant of the healthcare, logistic, and financial implications of recent trials and factored in these considerations in arriving at the class level of certain recommendations. 3. All recommendations in the PCI guideline update have been written in full sentences that express a complete thought, such that a recommendation, even if separated and presented apart from the rest of the document, will still convey the full intent of the recommendation. 4. The committee wishes to re-emphasize that the recommendations in the guideline apply to most patients but may require modification by existing situations that only the primary treating healthcare provider can evaluate properly. 5. The committee endeavored to maintain the consistency of recommendations in this and other previously pub- The classification of recommendations and levels of evidence are expressed in the ACC/AHA format as follows:
None
Routine measurement of cardiac biomarkers (CK-MB and/or troponin I or T) in all patients undergoing PCI is reasonable 8 to 12 hours after the procedure. (Level of Evidence: C)
Routine measurement of CK-MB or troponin I or T is added as a new class IIa, level of evidence C recommendation. The committee did not think that evidence regarding the clinical utility of routine measurement of biomarkers in all patients was strong enough to warrant a class I recommendation.
Institutional and Operator Competency 4.1 Quality Assurance
Class I Class I None 1. An institution that performs PCI should establish an ongoing mechanism for valid peer review of its quality and outcomes. Review should be conducted both at the level of the entire program and at the level of the individual practitioner. Quality-assessment reviews should take risk adjustment, statistical power, and national benchmark statistics into consideration. Quality-assessment reviews should include both tabulation of adverse event rates for comparison with benchmark values and case review of complicated procedures and some uncomplicated procedures. (Level of Evidence: C)
Quality assurance is an important responsibility for all institutions in which PCI is performed. Institutions must monitor the PCI program with respect to process, appropriateness, and outcomes and correct any circumstances in which quality falls below accepted norms. The quality assessment should be conducted at the level of both the entire program and the individual practitioner.
2. An institution that performs PCI should participate in a recognized PCI data registry for the purpose of benchmarking its outcomes against current national norms. (Level of Evidence: C)
Participation in a recognized PCI registry for benchmarking outcomes against current national norms is an important part of the quality-improvement process. The ACC-National Cardiovascular Data Registry® or other databases may serve as a valuable resource in this regard.
Operator and Institutional Volume

Class I Class I
PCI done by operators with acceptable volume (greater than or equal to 75) at high-volume centers (greater than 400). (Level of Evidence: B)
1. Elective PCI should be performed by operators with acceptable annual volume (at least 75 procedures) at high-volume centers (more than 400 procedures) with on-site cardiac surgery. (Level of Evidence: B)
Wording has been added to clarify this statement and emphasize that it relates to elective PCI performed at centers with on-site cardiac surgery.
2. Elective PCI should be performed by operators and institutions whose historical and current risk-adjusted outcomes statistics are comparable to those reported in contemporary national data registries. (Level of Evidence: C)
This recommendation was added to emphasize that historical and current risk-adjusted outcomes for operators and institutions are an essential part of the quality-improvement process. This recommendation is expanded based on data from the New York State registry indicating that physicians performing more than 10 primary PCI procedures per year have lower mortality rates (11) (12) (13) . Wording has been changed to comply with current recommended phrasing for class IIa recommendation. The fact that this recommendation applies to centers with on-site cardiac surgery is emphasized. Level of evidence has been changed to B based on accumulated published evidence (14) . Wording has been changed to comply with current recommended phasing. Level of evidence has been changed to B based on accumulated published evidence (15) .
Class IIa
Class IIb Class IIb
None
The benefit of primary PCI for STEMI patients eligible for fibrinolysis when performed by an operator who performs fewer than 75 procedures per year (or fewer than 11 PCIs for STEMI per year) is not well established. (Level of Evidence: C)
This recommendation has been added to address the issue of low-volume operators performing primary PCI. It reflects the relative lack of evidence supporting a benefit of primary PCI for low-volume operators. (29) . These recommendations may be subject to revision as clinical data and experience increase.
Class III
Phrasing has been changed to reflect current terminology. As with many dynamic areas in interventional cardiology, these recommendations may be subject to revision as clinical data and experience increase. Phrasing has been changed to reflect current terminology. Recommendations have been added that 1) physicians perform at least 11 primary PCIs per year for STEMI, 2) a 24 hours per day, 7 days per week call schedule be maintained, and 3) the catheterization laboratory be well equipped with digital imaging equipment, a full array of interventional equipment, and intra-aortic balloon pump capability. The intent is to ensure optimal experience availability and capability to perform primary PCI in patients with STEMI (16, 17) .
Class III Class III
Patients undergoing primary PCI in facilities without on-site cardiac surgery and without a proven plan for rapid access ( Phrasing has been changed to reflect current terminology and to place emphasis on need for inter-institutional planning and support.
Elective PCI Without On-Site Surgery
Class III Class III
Patients undergoing elective PCI in facilities without on-site cardiac surgery. (Level of Evidence: C)
Elective PCI should not be performed at institutions that do not provide on-site cardiac surgery. (Level of Evidence: C) *Several centers have reported satisfactory results based on careful case selection with well-defined arrangements for immediate transfer to a surgical program (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) . A small, but real fraction of patients undergoing elective PCI will experience a life-threatening complication that could be managed with the immediate on-site availability of cardiac surgical support but cannot be managed effectively by urgent transfer. Wennberg et al. found higher mortality in the Medicare database for patients undergoing elective PCI in institutions without onsite cardiac surgery (29) . These recommendations may be subject to revision as clinical data and experience increase.
Repeated from previous section for consistency. Phrasing has been changed to reflect current terminology.
Patients With Asymptomatic Ischemia or Canadian Cardiovascular Society (CCS) Class I or II Angina
Class I Class IIa
Patients who do not have treated diabetes with asymptomatic ischemia or mild angina with 1 or more significant lesions in 1 or 2 coronary arteries suitable for PCI with a high likelihood of success and a low risk of morbidity and mortality. The vessels to be dilated must subtend a large area of viable myocardium. (Level of Evidence: B)
1. PCI is reasonable in patients with asymptomatic ischemia or CCS class I or II angina and with 1 or more significant lesions in 1 or 2 coronary arteries suitable for PCI with a high likelihood of success and a low risk of morbidity and mortality. The vessels to be dilated must subtend a moderate to large area of viable myocardium or be associated with a moderate to severe degree of ischemia on noninvasive testing. (Level of Evidence: B)
Phrasing has been changed to reflect current terminology. This recommendation and all of those that follow in Section 5 have been reworded to be consistent with the CCS classification system of angina. This recommendation has been changed to class IIa to reflect the published data and Writing Committee consensus that not all patients in this clinical category must have PCI performed (30, 31) . This recommendation for PCI among patients who are eligible for CABG who have significant left main disease has been added to reflect the favorable results noted by several trials with PCI (32) (33) (34) (35) .
Class
Class IIb
Patients with asymptomatic ischemia or mild angina with greater than or equal to 3 coronary arteries suitable for PCI with a high likelihood of success and a low risk of morbidity and mortality. The vessels to be dilated must subtend at least a moderate area of viable myocardium. In the physician's judgment, there should be evidence of myocardial ischemia by ECG exercise testing, stress nuclear imaging, stress echocardiography or ambulatory ECG monitoring or intracoronary physiologic measurements.
(Level of Evidence: B)
This recommendation has been eliminated and replaced by the following 2 recommendations. For each, the phrasing has been constructed to reflect current terminology.
Class IIb
1. The effectiveness of PCI for patients with asymptomatic ischemia or CCS class I or II angina who have 2-or 3-vessel disease with significant proximal LAD CAD who are otherwise eligible for CABG with 1 arterial conduit and who have treated diabetes or abnormal LV function is not well established.
(Level of Evidence: B)
Phrasing has been changed to reflect current terminology. Among patients who are eligible, CABG with 1 arterial conduit is generally preferred for treatment of multivessel disease with significant proximal LAD obstruction in patients with treated diabetes and/or abnormal LV function (36).
PCI might be considered for patients with asymptomatic ischemia or CCS class I or II angina with nonproximal LAD CAD that subtends a moderate area of viable myocardium and demonstrates ischemia on noninvasive testing. (Level of Evidence: C)
Phrasing has been changed to reflect current terminology. PCI might be considered in this clinical setting. Phrasing has been changed to reflect current terminology. Recommendation has been reworded to be consistent with CCS classification system for angina. Level of evidence has been added for each subgroup.
Class III Class III
Patients With CCS Class III Angina
Class I Class IIa
Patients with 1 or more significant lesions in 1 or more coronary arteries suitable for PCI with a high likelihood of success and low risk of morbidity or mortality. The vessel(s) to be dilated must subtend a moderate or large area of viable myocardium and have high risk. (Level of Evidence: B)
1. It is reasonable that PCI be performed in patients with CCS class III angina and single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more significant lesions in 1 or more coronary arteries suitable for PCI with a high likelihood of success and low risk of morbidity or mortality. (Level of Evidence: B)
Phrasing has been changed to reflect current terminology. Recommendation has been reworded to be consistent with CCS classification system for angina. The recommendation class has been changed to IIa to reflect published data and Writing Committee consensus. Criteria regarding viable and high-risk myocardium have been deleted from this recommendation (30, 31) . This recommendation for PCI among patients with significant left main disease who are not eligible for CABG has been added to reflect the favorable results noted by several trials with PCI (32) (33) (34) (35) .
Class IIb Class IIb
Patient has 1 or more lesions to be dilated with reduced likelihood of success or the vessel(s) subtend a less than moderate area of viable myocardium. Patients with 2-or 3-vessel disease, with significant proximal LAD CAD and treated diabetes or abnormal LV function.
(Level of Evidence: B)
1. PCI may be considered in patients with CCS class III angina with single-vessel or multivessel CAD who are undergoing medical therapy and who have 1 or more lesions to be dilated with a reduced likelihood of success. Phrasing has been changed to reflect current terminology. The use of noninvasive testing to evaluate for evidence of ischemia has been added.
Class III Class III
Patient has no evidence of myocardial injury or ischemia on objective testing and has not had a trial of medical therapy, or has a. Only a small area of myocardium at risk b. All lesions or the culprit lesion to be dilated with morphology with a low likelihood of success c. A high risk of procedure-related morbidity or mortality. Phrasing has been changed to reflect current terminology. Recommendation has been divided to emphasize specific points. The class IIb recommendation was upgraded in the ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction and approved by the PCI Writing Committee.
PCI in Fibrinolytic-Ineligible Patients
Class IIa Class I
As a reperfusion strategy in candidates who have a contraindication to thrombolytic therapy. 
Class IIa
It is reasonable to perform primary PCI for fibrinolytic-ineligible patients with onset of symptoms within the prior 12 to 24 hours and 1 or more of the following: 
Facilitated PCI
Class IIb Class IIb
None Facilitated PCI might be performed as a reperfusion strategy in higher-risk patients when PCI is not immediately available and bleeding risk is low. (Level of Evidence: B)
New recommendation from the ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction addressing conditions for which facilitated PCI might be considered. Important randomized trials are under way, and more data are needed regarding outcomes resulting from this treatment strategy (57-63). Phrasing has been changed to reflect current terminology.
PCI After Failed Fibrinolysis (Rescue PCI)
Class I Class
Class IIb
Recurrent angina without objective evidence of ischemia/infarction.
(Level of Evidence: C)
Deleted. Recurrent angina is not applicable to rescue angioplasty. Recurrent symptoms are discussed elsewhere.
Class III Class III
Routine PTCA within 48 h following failed thrombolysis. (Level of Evidence: B)
Rescue PCI in the absence of 1 or more of the above class I or IIa indications is not recommended. (Level of Evidence: C)
Evidence obtained from studies of PTCA during the fibrinolytic era before the use of stents failed to show a benefit for reperfusion under these conditions. Current trials are under way to investigate the outcome of PCI with stent placement among patients with occluded arteries days after presentation with STEMI.
PCI After Successful Fibrinolysis or for Patients Not Undergoing Primary Reperfusion
Class I Class I Phrasing has been changed to reflect current terminology. Level of evidence was revised on the basis of review by the Writing Committee, and cardiogenic shock has been added (cardiogenic shock is discussed in Section 5.4.6 and is a class I, level of evidence A recommendation for patients younger than 75 years old and a class IIa, level of evidence B recommendation for those aged 75 years and older) (49) .
Class IIa Class IIa
Patients with LV ejection fraction less than or equal to 0.4, CHF, or serious ventricular arrhythmias. (Level of Evidence: C)
1. It is reasonable to perform routine PCI in patients with LV ejection fraction less than or equal to 0.40, CHF, or serious ventricular arrhythmias. (Level of Evidence: C)
Phrasing has been changed to reflect current terminology. This recommendation has been upgraded to class IIb to reflect a possible benefit from improved technology. The Committee recognizes the potential benefit of this therapy but believes more data are needed to define outcomes of PCI after fibrinolytic therapy in the current era of improved antiplatelet, anticoagulant, and drug-eluting stent therapies.
Class
PCI for Cardiogenic Shock
Class I Class I
None Primary PCI is recommended for patients less than 75 years old with ST elevation or LBBB who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of shock, unless further support is futile because of the patient's wishes or contraindications/unsuitability for further invasive care.
(Level of Evidence: A)
Phrasing has been changed to reflect current terminology and the ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (48) (49) (50) (51) (52) (53) .
Class IIa Class IIa
Cardiogenic shock or hemodynamic instability. (Level of Evidence: B)
Primary PCI is reasonable for selected patients 75 years or older with ST elevation or LBBB who develop shock within 36 hours of MI and are suitable for revascularization that can be performed within 18 hours of shock. Patients with good prior functional status who are suitable for revascularization and agree to invasive care may be selected for such an invasive strategy.
(Level of Evidence: B)
Phrasing has been changed to reflect current technology and modified to be consistent with the ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (48-53).
Percutaneous Intervention in Patients With Prior Coronary Bypass Surgery
Class I Class I
Patients with early ischemia (usually within 30 days) after CABG (194 Phrasing has been changed to reflect current terminology.
It is recommended that distal embolic protection devices be used when technically feasible in patients undergoing PCI to saphenous vein grafts. (Level of Evidence: B)
New recommendation is based on several studies demonstrating efficacy of distal embolic protection devices in PCI to saphenous vein grafts (65, 66) . Phrasing has been changed to reflect current technology, and considerations regarding risk of repeat CABG have been added (36). Phrasing has been changed to reflect current terminology. The previous class IIa recommendations for IVUS have been listed together in the recommendation rather than separately, with the exception that the Writing Committee has changed the recommendation to evaluate coronary disease after transplantation to class IIb. Phrasing has been changed to reflect current terminology. The previous class IIb recommendations for IVUS have been listed together in this recommendation rather than separately. The use of IVUS to evaluate coronary disease in transplant patients is now a class IIb recommendation.
Class IIa Class IIa
Intravascular Ultrasound Imaging (IVUS)
Class IIa
Class III Class III
When angiographic diagnosis is clear and no interventional treatment is planned. Phrasing has been changed to reflect current terminology.
Class IIb Class IIb
1. Evaluation of the success of percutaneous coronary revascularization in restoring flow reserve and to predict the risk of restenosis. (Level of Evidence: C)
1. Intracoronary physiologic measurements may be considered for the evaluation of the success of PCI in restoring flow reserve and to predict the risk of restenosis.
(Level of Evidence: C)
Phrasing has been changed to reflect current terminology.
Evaluation of patients with anginal symptoms without an apparent angiographic culprit lesion. (Level of Evidence: C)
2. Intracoronary physiologic measurements may be considered for the evaluation of patients with anginal symptoms without an apparent angiographic culprit lesion.
(Level of Evidence: C)
Class III Class III
Routine assessment of the severity of angiographic disease in patients with a positive, unequivocal noninvasive functional study. (Level of Evidence: C)
Routine assessment with intracoronary physiologic measurements such as Doppler ultrasound or fractional flow reserve to assess the severity of angiographic disease in patients with a positive, unequivocal noninvasive functional study is not recommended.
(Level of Evidence: C)
Phrasing has been changed to reflect current terminology. Clopidogrel is an important adjunctive therapy for patients undergoing PCI with stent placement. The best evidence of efficacy exists for 300 mg given at least 6 hours before PCI is performed (68, 69, 72) . 5 . In patients who have undergone PCI, clopidogrel 75 mg daily should be given for at least 1 month after bare-metal stent implantation (unless the patient is at increased risk for bleeding; then it should be given for a minimum of 2 weeks), 3 months after sirolimus stent implantation, and 6 months after paclitaxel stent implantation, and ideally up to 12 months in patients who are not at high risk of bleeding. (Level of Evidence: B)
Management of Patients
Clopidogrel therapy in the dosage of 75 mg daily should be given after stent placement to all patients. The duration of therapy varies for each stent and is based on data from clinical trials used for US Food and Drug Administration approval of that stent (67, (69) (70) (71) .
Class IIa
1. If clopidogrel is given at the time of procedure, supplementation with GP IIb/IIIa receptor antagonists can be beneficial to facilitate earlier platelet inhibition than with clopidogrel alone. A significant number of patients will have resistance to aspirin. The strongest evidence for clopidogrel benefit exists for doses of 300 mg given at least 6 hours before the procedure.
3. When a loading dose of clopidogrel is administered, a regimen of greater than 300 mg is reasonable to achieve higher levels of antiplatelet activity more rapidly, but the efficacy and safety compared with a 300-mg loading dose are less established. (Level of Evidence: C)
Many patients receive clopidogrel therapy at the time of PCI in dosages greater than 600 mg. Although more pronounced inhibition of platelet function has been demonstrated for doses of clopidogrel greater than 300 mg, the safety of these higher doses and their benefits on clinical outcome are not fully established.
4. It is reasonable that patients undergoing brachytherapy be given daily clopidogrel 75 mg indefinitely and daily aspirin 75 to 325 mg indefinitely unless there is significant risk for bleeding. (Level of Evidence: C) Subacute or later thrombosis has been observed in patients undergoing brachytherapy, and for this reason long-term antiplatelet therapy is recommended.
Class IIb
In patients in whom subacute thrombosis may be catastrophic or lethal (unprotected left main, bifurcating left main, or last patent coronary vessel), platelet aggregation studies may be considered and the dose of clopidogrel increased to 150 mg per day if less than 50% inhibition of platelet aggregation is demonstrated.
(Level of Evidence: C)
Clopidogrel resistance is a significant problem, and owing to its contribution to catastrophic clinical outcomes, the Writing Committee recommends studies be performed with increases in clopidogrel dose being recommended for use in those with higher-risk lesions.
Glycoprotein IIb/IIIa Inhibitors
Class I
The recommendations in this section appeared in Recommendation from the ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction has been approved by this Writing Committee and included in these guidelines for consistency.
Class IIa Class IIa
Left Main CAD
Class IIa None
Class IIa
It is reasonable that patients undergoing PCI to unprotected left main coronary obstructions be followed up with coronary angiography between 2 and 6 months after PCI. (Level of Evidence: C)
Patients undergoing PCI to an unprotected left main coronary artery are at higher risk for adverse events and should be monitored carefully. On the basis of experience and opinion in the available reports, the Writing Committee recommends angiography be performed between 2 and 6 months after PCI.
Management Strategies for Restenosis After PTCA
Class IIa Class IIa
None It is reasonable to consider that patients who develop restenosis after PTCA or PTCA with atheroablative devices are candidates for repeat coronary intervention with intracoronary stents if anatomic factors are appropriate. (Level of Evidence: B)
This new recommendation reflects data indicating a significant reduction in target-lesion revascularization and restenosis for patients undergoing bare-metal stent placement compared with PTCA for restenosis after PTCA (84).
Drug-Eluting Stents
Class I None
Class I
A drug-eluting stent should be considered as an alternative to the bare-metal stent in subsets of patients in whom trial data suggest efficacy. (Level of Evidence: A)
New recommendation since the 2001 ACC/AHA Guidelines for Percutaneous Coronary Intervention. Evidence continues to accumulate that supports the use of drug-eluting stents (DES) versus bare-metal stents in certain subsets in which DES results and outcomes are better (70, 71, (85) (86) (87) (88) (89) (90) (91) (92) (93) (94) (95) (96) (97) .
Class IIb None
Class IIb
A drug-eluting stent may be considered for use in anatomic settings in which the usefulness, effectiveness, and safety have not been fully documented in published trials. (Level of Evidence: C)
The data that a DES can improve clinical outcomes for PCI are generally strong. However, DESs have not undergone evaluation for use in all clinical situations and anatomic settings. 
